Mitsui Chemicals, Inc.

Norikazu Higashimura

Kazuo Sugamura

Kazuya Matsumoto

Yasushi Kazuno

Haruhiko Sakuraba

Toshihisa Ohshima

Kazuko Murata

An industrial process for producing hydroxyaldehydes efficiently, by solving the problems of conventional DERA, such as low stability against aldehydes, low catalytic activity for aldol condensation, and the difficulty of controlling the number of acetaldehyde molecules to be condensed, is provided. According to the process, aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with acetaldehyde is conducted by using D-2-deoxyribose-5-phosphate aldolase which is highly stable against aldehydes and has high catalytic activity for aldol condensation, whereby a hydroxyaldehyde compound having the number of carbon atoms increased by two or four can be produced.

Process for producing chiral hydroxyaldehyde compounds

The present invention relates to a pharmaceutical composition for the therapeutic treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, sarcoidosis, autoimmune uveitis, and inflammatory bowel disease, or graft-versus-host disease. The pharmaceutical composition contains, as the effective ingredient, a gp34 binding-inhibitory substance.

Medicinal composition containing gp34 binding-inhibitor as the active ingredient

Growing community of inventors

Mobara, Japan

Norikazu Higashimura